Staar Surgical price target lowered to $40 from $45 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Staar Surgical to $40 from $45 and keeps a Neutral rating on the shares. The firm notes Staar reported Q3 results with ICL revenues that came in-line with its target alongside an EPS beat. However, declining sequential domestic sales, a rapidly slowing China growth number and revenue guidance that is now expected to be on the low end of Staar’s prior range will likely weigh on shares, Piper says.